MAGEA4 plasmid vector基因表达质粒编辑敲除载体 BioVector NTCC质粒载体菌种细胞基因保藏中心
- 价 格：¥29865
- 货 号：MAGEA4 plasmid vector基因表达质粒编辑敲除载体
- 产 地：北京
- BioVector NTCC典型培养物保藏中心
- 联系人：Dr.Xu, Biovector NTCC Inc.
电话：400-800-2947 工作微信:1843439339 (QQ同号)
邮件：Biovector@163.com
手机：18901268599
地址：北京
- 已注册
MAGEA4 plasmid vector基因表达质粒编辑敲除载体
Melanoma Antigen Gene (MAGE) type A4 acts as an activator of Trans-lesion synthesis, an error-prone mechanism for DNA repair. Interest in the antigen began when the MAGE proteins were found to only express in the testes, placenta, and several types of tumors. This differentiation made MAGEA4 a perfect immunotherapeutic target, and the excitement in the research community ignited. A cancer vaccine targeting MAGEA4 entered clinical trials in 2009. Interest peaked when MAGEA4 was identified as present in some of the most dangerous malignant tumors types. Today MAGEA4 shows up as a target in clinical trials in the US, China, and Japan including this experiential treatment for Rhabdomyosarcoma.
Supplier来源:BioVector NTCC Inc.
TEL电话:+86-010-53513060
Website网址: http://www.biovector.net
Melanoma Antigen Gene (MAGE) type A4 acts as an activator of Trans-lesion synthesis, an error-prone mechanism for DNA repair. Interest in the antigen began when the MAGE proteins were found to only express in the testes, placenta, and several types of tumors. This differentiation made MAGEA4 a perfect immunotherapeutic target, and the excitement in the research community ignited. A cancer vaccine targeting MAGEA4 entered clinical trials in 2009. Interest peaked when MAGEA4 was identified as present in some of the most dangerous malignant tumors types. Today MAGEA4 shows up as a target in clinical trials in the US, China, and Japan including this experiential treatment for Rhabdomyosarcoma.
Supplier来源:BioVector NTCC Inc.
TEL电话:+86-010-53513060
Website网址: http://www.biovector.net
- 公告/新闻
